Utama › Skleroderma › California
Kajian klinikal Skleroderma di California
13 kajian untuk Skleroderma sedang mencari peserta di lokasi di California.
Bandar di California
Teks kajian rasmi (Bahasa Inggeris)
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- University of California Los Angeles, Los Angeles
- Paradigm Clinical Research - San Diego, San Diego
- Stanford University School of Medicine, Stanford
- dan 1 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07497087A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
- UCLA Ronald Reagan University of California Los Angeles Medical Center, Los Angeles
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06655155Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- University of California Davis Comprehensive Cancer Center, Sacramento
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT03816345A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Loma Linda University Medical Center, Loma Linda
Mengambil pesertaFasa 1
Umur 18 hingga 74 · Semua jantina · Dikemas kini 10 Sep 2026 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- dan 1 lagi
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT05878717FT839 in Autoimmune Diseases
- Providence Medical Foundation, Fullerton
Mengambil pesertaFasa 1/2
Umur 18 hingga 70 · Semua jantina · Dikemas kini 2 Sep 2026 · NCT07800871A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- UC San Diego Health, La Jolla
- Stanford University Medical Center, Redwood City
Mengambil pesertaFasa 1
Umur 18 hingga 70 · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT06925542Platform Clinical Study for Conquering Scleroderma
- Keck School of Medicine at USC Medical Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Stanford University Medical Center, Palo Alto
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Ogo 2026 · NCT06195072A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Orange
Mengambil pesertaFasa 1/2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Chula Vista, Chula Vista
- Artiva Investigational Site Covina, Covina
- Artiva Investigational Site Los Alamitos, Los Alamitos
- dan 3 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Jul 2026 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
- Research Site, Stanford
Mengambil pesertaFasa 1
Umur 18 hingga 75 · Semua jantina · Dikemas kini 28 Jul 2026 · NCT07295847A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Wallace Rheumatic Center, Beverly Hills
- Providence Medical Foundation, Fullerton
- University of California Irvine, Irvine
- dan 2 lagi
Mengambil pesertaFasa 1
Umur 12 hingga 70 · Semua jantina · Dikemas kini 22 Mei 2026 · NCT06308978Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Los Angeles
- aTyr Investigative Site, San Diego
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Mei 2025 · NCT05892614Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.